Latent class analysis of over 48,000 UK Biobank participants with MRI-defined hepatic steatosis reveals distinct MASLD clinical subtypes with strong sex-based differences.
A novel four-protein biomarker panel (PS4), linked to lipid metabolism and immune pathways, predicts all-cause mortality more accurately than existing non-invasive scores.
Proteomic components mediate 10-20% of the mortality risk attributable to MASLD phenotypic classes, highlighting key biological pathways driving systemic outcomes.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
